Rani Therapeutics Holdings, Inc. financial data

Symbol
RANI on Nasdaq
Location
2051 Ringwood Avenue, San Jose, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 6, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 414 % -74.2%
Debt-to-equity 357 % +280%
Return On Equity -152 % -199%
Return On Assets -54.2 % -56.1%

Shares

Label TTM Value / Value Unit Change %
Entity Public Float 54.1M USD -57.8%
Weighted Average Number of Shares Outstanding, Basic 26.3M shares +3.86%
Weighted Average Number of Shares Outstanding, Diluted 26.3M shares +3.86%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD
Research and Development Expense 32.5M USD -19.3%
General and Administrative Expense 25.3M USD -10.7%
Operating Income (Loss) -57.8M USD +15.7%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -67.9M USD -7.28%
Income Tax Expense (Benefit) 0 USD -100%
Net Income (Loss) Attributable to Parent -30.6M USD +11.1%
Earnings Per Share, Basic -1.18 USD/shares +54.3%
Earnings Per Share, Diluted -1.18 USD/shares +54.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 4.51M USD -40.2%
Marketable Securities, Current 98.5M USD
Assets, Current 32M USD -58.1%
Property, Plant and Equipment, Net 5.7M USD -4.11%
Operating Lease, Right-of-Use Asset 5.75M USD +382%
Other Assets, Noncurrent 246K USD
Assets 43.7M USD -47.6%
Accounts Payable, Current 506K USD -51.2%
Accrued Liabilities, Current 2.3M USD +60.1%
Liabilities, Current 16.6M USD +189%
Operating Lease, Liability, Noncurrent 4.39M USD +1198%
Liabilities 38.2M USD +8.03%
Accumulated Other Comprehensive Income (Loss), Net of Tax -5K USD +92.1%
Retained Earnings (Accumulated Deficit) -87.2M USD -54%
Stockholders' Equity Attributable to Parent 2.84M USD -88.2%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 5.55M USD -88.5%
Liabilities and Equity 43.7M USD -47.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -9.4M USD +22.6%
Net Cash Provided by (Used in) Financing Activities 121K USD +1413%
Net Cash Provided by (Used in) Investing Activities 10.3M USD +150%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 1.01M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 5.01M USD -37.7%
Deferred Tax Assets, Valuation Allowance 61M USD +15.5%
Deferred Tax Assets, Gross 61M USD +15.5%
Operating Lease, Liability 5.75M USD +382%
Depreciation 111K USD -18.4%
Payments to Acquire Property, Plant, and Equipment 18K USD -92.7%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -30.5M USD +11.5%
Lessee, Operating Lease, Liability, to be Paid 7.13M USD +460%
Property, Plant and Equipment, Gross 5.87M USD +31.3%
Operating Lease, Liability, Current 1.36M USD +59.2%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.9M USD +264%
Lessee, Operating Lease, Liability, to be Paid, Year One 930K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.38M USD +1664%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.23M USD +64.1%
Deferred Tax Assets, Operating Loss Carryforwards 13M USD +90.7%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 20M shares 0%
Unrecognized Tax Benefits 489K USD +132%
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.28M USD
Operating Lease, Payments 180K USD -30.5%
Additional Paid in Capital 90M USD +11.5%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 18.9M USD +1.07%
Share-based Payment Arrangement, Expense 15.8M USD -30.2%
Interest Expense 5.18M USD +46.2%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%